Reinfusion of Cell-Free and Concentrated Autogenous Ascitic Fluid for Intractable Ascites in the Terminal Cancer Patient

This is the authors' abstract. We don't add key points for this paper.

Intravenous reinfusion of autogenous ascitic fluid was primarily applied for intractable ascites in the cirrhotic patient. Recently, this procedure was modified using a technique of cell removal and fluid concentration and applied for intractable ascites in the terminal cancer patient. In the present study, the effect of the reinfusion of cell-free and concentrated autogenous ascitic fluid for in-tractable ascites in the terminal cancer patient was evaluated. Fourteen cases of terminal cancer with intractable ascites were treated with 21 reinfusions. The reinfusion was effective in 85.7% of the cases decreasing the complaints caused by ascitic retension. It caused neither hypoprotenemia nor imbalance of serum electrolytes. In addition, the repeated reinfusion led to a restraint of the re-retension of ascitic fluid. Although pyrexia occurred in 71.4% of the reinfusions, in most of the cases, this was subsided with the administration of the usual antipyretics. These results indicate that the reinfusion of cell-free and concentrated autogenous ascitic fluid is useful for the control of intractable ascites in the terminal cancer patient.